prof. MUDr. Jiří Mayer, CSc.
Department head, Department of Internal Medicine, Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
phone: | +420 532 23 3643, 3603 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 1630
2023
-
Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL.
Year: 2023, type: Conference abstract
-
Transkripční faktor FoxO1 v adaptaci chronické lymfocytární leukémie na cílenou léčbu.
Year: 2023, type: Conference abstract
-
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
Communications Medicine, year: 2023, volume: 3, edition: 1, DOI
-
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine, year: 2023, volume: 388, edition: 4, DOI
-
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
Journal of clinical oncology, year: 2023, volume: 41, edition: 5, DOI
2022
-
Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft
Year: 2022, type: Conference abstract
-
Adaptace buněk chronické lymfocytární leukémie na cílenou léčbu BCR inhibitory.
Year: 2022, type: Conference abstract
-
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia
American Journal of Hematology, year: 2022, volume: 97, edition: 9, DOI
-
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia
Future Oncology, year: 2022, volume: 18, edition: 26, DOI
-
Dosavadní zkušenosti s léčbou ropeginterferonem alfa-2b u pacientů s Ph negativními myeloproliferacemi na Interní hematologické a onkologické klinice LF MU a FN Brno
Transfuze a Hematologie Dnes, year: 2022, volume: 28, edition: 4, DOI